1.Benhamou D, Lienhart A, Auroy Y, Péquignot F, Jougla E. Accidents by ABO incompatibility and other main complications related to blood transfusion in surgical patients: data from the French national survey on anaesthesia-related deaths. Transfus Clin Biol. 2005 Nov;12(5):389–90.
Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005 Feb;34(1):121–30.
Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005 Jun;42(6):799–805.
Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005;37(6–7):482–7.
1.Rey G, Jougla E. Are alcohol-attributable mortality estimates reliable? Eur J Public Health. 2014 Feb;24(1):3–4.
1.Lamarche-Vadel A, Pavillon G, Aouba A, Johansson LA, Meyer L, Jougla E, et al. Automated comparison of last hospital main diagnosis and underlying cause of death ICD10 codes, France, 2008-2009. BMC Med Inform Decis Mak. 2014;14:44.
1.Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May 15;28(8):1181–91.
1.Viallon V, Banerjee O, Jougla E, Rey G, Coste J. Empirical comparison study of approximate methods for structure selection in binary graphical models. Biom J. 2014 Mar;56(2):307–31.
1.Vuillermoz C, Aouba A, Grout L, Vandentorren S, Tassin F, Vazifeh L, et al. Estimating the number of homeless deaths in France, 2008-2010. BMC Public Health. 2014;14:690.
Saucedo M, Bouvier-Colle MH, Chantry AA, Lamarche-Vadel A, Rey G, Deneux-Tharaux C. Pitfalls of national routine death statistics for maternal mortality study. Paediatr Perinat Epidemiol. 2014 Nov;28(6):479–88.
Lefeuvre D, Pavillon G, Aouba A, Lamarche-Vadel A, Fouillet A, Jougla E, et al. Quality comparison of electronic versus paper death certificates in France, 2010. Popul Health Metr. 2014;12(1):3.
Romon I, Rey G, Mandereau-Bruno L, Weill A, Jougla E, Eschwège E, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes--the 2001-2006 ENTRED cohort. Diabet Med. 2014 Aug;31(8):946–53.
1.Westerling R, Westin M, McKee M, Hoffmann R, Plug I, Rey G, et al. The timing of introduction of pharmaceutical innovations in seven European countries. J Eval Clin Pract. 2014 Aug;20(4):301–10.
1.Chiche L, Jourde-Chiche N, Bader-Meunier B, Retornaz F, Malaekah S, Eb M, et al. Acute pancreatitis as a cause of mortality in pediatric systemic lupus erythematosus: Results of a multiple cause-of-death analysis in France. Semin Arthritis Rheum. 2016 Mar 16;
1.Vuillermoz C, Aouba A, Grout L, Vandentorren S, Tassin F, Moreno-Betancur M, et al. Mortality among homeless people in France, 2008-10. Eur J Public Health. 2016 Jun 21;
Piffaretti C, Moreno-Betancur M, Lamarche-Vadel A, Rey G. Quantifying cause-related mortality by weighting multiple causes of death. Bull World Health Organ. 2016 Dec 1;94(12):870–9.
Jamilloux Y, Maucort-Boulch D, Kerever S, Gerfaud-Valentin M, Broussolle C, Eb M, et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J. 2016 Sep 22;
Temam S, Varraso R, Pornet C, Sanchez M, Affret A, Jacquemin B, et al. Ability of ecological deprivation indices to measure social inequalities in a French cohort. BMC Public Health. 2017 Dec 15;17(1):956.
1.Ghosn W, Menvielle G, Rican S, Rey G. Associations of cause-specific mortality with area level deprivation and travel time to health care in France from 1990 to 2007, a multilevel analysis. BMC Public Health. 2017 Aug 2;18(1):86.
1.Mercereau L, Todd N, Rey G, Valleron AJ. Comparison of the temperature-mortality relationship in foreign born and native born died in France between 2000 and 2009. Int J Biometeorol. 2017 May 25;
1.Pouessel G, Claverie C, Labreuche J, Dorkenoo A, Renaudin JM, Eb M, et al. Fatal anaphylaxis in France: analysis of national anaphylaxis data, 1979-201J Allergy Clin Immunol. 2017 Mar 7;
1.Ngantcha M, Le-Pogam MA, Calmus S, Grenier C, Evrard I, Lamarche-Vadel A, et al. Hospital quality measures: are process indicators associated with hospital standardized mortality ratios in French acute care hospitals? BMC Health Serv Res. 2017 Aug 22;17(1):578.
1.Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017 Aug 23;
1.Avouac J, Amrouche F, Meune C, Rey G, Kahan A, Allanore Y. Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. Semin Arthritis Rheum. 2017 Apr;46(5):537–43.
1.Affret A, Severi G, Dow C, Rey G, Delpierre C, Boutron-Ruault MC, et al. Socio-economic factors associated with a healthy diet: results from the E3N study. Public Health Nutr. 2017 Jun;20(9):1574–83.
1.Moreno-Betancur M, Sadaoui H, Piffaretti C, Rey G. Survival Analysis with Multiple Causes of Death: Extending the Competing Risks Model. Epidemiology. 2017 Jan;28(1):12–9.
Rey G, Bounebache K, Rondet C. Causes of deaths data, linkages and big data perspectives. J Forensic Leg Med. 2018 Jul;57:37–40.
Chazal T, Lhote R, Rey G, Haroche J, Eb M, Amoura Z, et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmun Rev. 2018 Dec;17(12):1219–24.
Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, et al. Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). Rheumatology (Oxford). 2018 Jun 1;57(6):1047–55.
Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239–48.